Journal article

Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD

Kathryn V Papp, Rachel Buckley, Elizabeth Mormino, Paul Maruff, Victor L Villemagne, Colin L Masters, Keith A Johnson, Dorene M Rentz, Reisa A Sperling, Rebecca E Amariglio

Alzheimer's & Dementia | WILEY | Published : 2020


INTRODUCTION: Demonstrating the "clinical meaningfulness" of slowing early cognitive decline in clinically normal (CN) older adults with elevated amyloid-β (Aβ+) is critical for Alzheimer's disease secondary prevention trials and for understanding early cognitive progression. METHODS: Cox regression analyses were used to determine whether 3-year slopes on the preclinical Alzheimer's cognitive composite predicted MCI diagnosis and global Clinical Dementia Rating>0 in 267 Aβ+ CN individuals participating in the Harvard Aging Brain Study, Australian Imaging, Biomarker and Lifestyle Study, and Alzheimer's Disease Neuroimaging Initiative. RESULTS: Steeper preclinical Alzheimer's cognitive composi..

View full abstract


Awarded by National Institute on Aging

Awarded by NIA

Awarded by National Institutes of Health

Awarded by DOD

Funding Acknowledgements

National Institute on Aging, Grant/Award Number: P01AG036694; NIA, Grant/Award Number: 1K23AG053422-01; Alzheimer's Association; Alzheimer's Disease Neuroimaging Initiative; National Institutes of Health, Grant/Award Number: AG024904; DOD, Grant/Award Number: W81XWH-12-2-0012; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Canadian Institutes of Health Research; Australian Commonwealth Scientific Industrial and research Organization; Edith Cowan University; Mental Health Research Institute; Alzheimer's Australia; Hollywood Private Hospital; National Health and Medical Research Council; Science and Industry Endowment Fund